Cargando…

The promise of Immuno-oncology: implications for defining the value of cancer treatment

The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts to generate value assessments for novel therapies, multiple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaufman, Howard L., Atkins, Michael B., Subedi, Prasun, Wu, James, Chambers, James, Joseph Mattingly, T., Campbell, Jonathan D., Allen, Jeff, Ferris, Andrea E., Schilsky, Richard L., Danielson, Daniel, Lichtenfeld, J. Leonard, House, Linda, Selig, Wendy K. D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Position Article and Guidelines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525438/ https://www.ncbi.nlm.nih.gov/pubmed/31101066 http://dx.doi.org/10.1186/s40425-019-0594-0

Ejemplares similares

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement
por: Tsimberidou, Apostolia M., et al.
Publicado: (2018)

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
por: Atkins, Michael B, et al.
Publicado: (2022)

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
por: Kluger, Harriet M., et al.
Publicado: (2020)

Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit
por: Pai, Sara, et al.
Publicado: (2020)

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs
por: Zhang, Tian, et al.
Publicado: (2023)

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
por: Atkins, Michael B, et al.
Publicado: (2023)

Neoadjuvant immunotherapy of locoregionally advanced solid tumors
por: Tarhini, Ahmad A, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
por: Rizvi, Naiyer, et al.
Publicado: (2023)

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
por: Sullivan, Ryan J., et al.
Publicado: (2018)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
por: Govindan, Ramaswamy, et al.
Publicado: (2022)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
por: Puzanov, I., et al.
Publicado: (2017)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie R., et al.
Publicado: (2018)

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
por: Quinn, Casey, et al.
Publicado: (2020)

Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO)
por: Cianferotti, Luisella, et al.
Publicado: (2017)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
por: McNeel, Douglas G., et al.
Publicado: (2016)

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
por: Rini, Brian I., et al.
Publicado: (2019)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
por: Rini, Brian I., et al.
Publicado: (2016)

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)
por: Lambert, J.L.W., et al.
Publicado: (2020)

Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 1)
por: Lambert, J.L.W., et al.
Publicado: (2020)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
por: Guidon, Amanda C, et al.
Publicado: (2021)

Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement
por: Gambaro, Giovanni, et al.
Publicado: (2016)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
por: Maus, Marcela V, et al.
Publicado: (2020)

European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I
por: Rashid, H., et al.
Publicado: (2021)

European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II
por: Schmidt, E., et al.
Publicado: (2021)

Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA(2)LEN)
por: Braido, F., et al.
Publicado: (2016)

Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA(2)LEN)
por: Braido, F., et al.
Publicado: (2019)

Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel
por: Togias, Alkis, et al.
Publicado: (2017)

Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel
por: Togias, Alkis, et al.
Publicado: (2017)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
por: Shah, Nina, et al.
Publicado: (2020)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
por: Boyiadzis, Michael, et al.
Publicado: (2016)

Guidelines for immunological analyses following focused ultrasound treatment
por: Padilla, Frederic, et al.
Publicado: (2023)

Early introduction is not enough: CSACI statement on the importance of ongoing regular ingestion as a means of food allergy prevention
por: Abrams, Elissa M., et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
por: Galsky, Matthew D, et al.
Publicado: (2021)

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
por: Hu-Lieskovan, Siwen, et al.
Publicado: (2020)

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement
por: Leshem, Y.A., et al.
Publicado: (2019)

It’s not ‘just a tube of blood’: principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studies
por: Jiang, Cindy Y, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_al2jrc9nmf0ngts2qip3eimiga